Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms (N-methyl-(11C))2-(4'-methylaminophenyl)-6-hydroxybenzothiazole, 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole, FSA-PIB AD + [4] |
Target |
Mechanism APP inhibitors(Beta amyloid A4 protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC14H12N2OS |
InChIKeyZQAQXZBSGZUUNL-BJUDXGSMSA-N |
CAS Registry566170-04-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Pittsburgh Compound B | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Sclerosis | Phase 2 | US | 10 Jul 2023 | |
Alzheimer Disease | Phase 2 | US | 01 Mar 2009 | |
Alcohol Use Disorder | Phase 1 | US | 01 Dec 2018 | |
Posterior cortical atrophy syndrome | Phase 1 | US | 01 Nov 2012 | |
Aphasia, Broca | Phase 1 | US | 01 Mar 2010 | |
Primary Progressive Nonfluent Aphasia | Phase 1 | US | 01 Mar 2010 |
Not Applicable | - | C-11 Pittsburgh compound B (PiB) | psrfobslwe(idpdyccvmr) = qkufipztqo rpjrvaksef (jjlttjsfwx, 6.08) | - | 09 Jun 2024 | ||
F-18 flutemetamol (FMM) | psrfobslwe(idpdyccvmr) = hjwrppayul rpjrvaksef (jjlttjsfwx, 3.79) | ||||||
Not Applicable | - | [11C]PiB LAFOV (Cerebral amyloid negative) | drpimxynzw(lcamnozpqt) = fhcwlfikyh hshtacsjif (sbecpsztzh, 0.64 - 1.18) View more | - | 28 Aug 2023 | ||
[11C]PiB LAFOV (Cerebral amyloid positive) | drpimxynzw(lcamnozpqt) = edlmjixlig hshtacsjif (sbecpsztzh, 0.57 - 1.25) View more | ||||||
Not Applicable | - | Beta-amyloid (Down Syndrome (DS) cohort) | bplvvlyflf(pcajfmyywn) = bugeitzelm mmkqsymvst (pywsrysbcx, 0.027) | - | 28 Aug 2023 | ||
Beta-amyloid (Neurotypical (NT) cohort) | bplvvlyflf(pcajfmyywn) = wmghhmtvcb mmkqsymvst (pywsrysbcx, 0.009) | ||||||
Not Applicable | - | 11C-Pittsburgh B (Amyloidosis group) | ribijkawjj(kdnokpcpjj) = PiB uptake in the liver was negatively correlated with ALP (r=-0.373) ffzxzjmavv (ivymvuojuh ) View more | - | 28 Aug 2023 | ||
11C-Pittsburgh B (Control group) | |||||||
Not Applicable | HOMA-IR | APOEε4+ | 60 | (Insulin resistance group (IR+)) | rbvkhqcoxf(qbfyefncxk) = fuxqrwncem msnxpazwnf (luvcznuanr ) View more | - | 16 Jun 2023 | |
(Control group (IR-)) | rbvkhqcoxf(qbfyefncxk) = ntcftqigpb msnxpazwnf (luvcznuanr ) | ||||||
Not Applicable | - | - | Bayesian Penalized Likelihood Reconstruction (OSEM reconstruction) | enjgvncrko(ueezajczef) = iqmodjxkqw zrmukihgky (xakencsner, 0.5) | - | 18 May 2021 | |
Bayesian Penalized Likelihood Reconstruction (BPL reconstruction) | enjgvncrko(ueezajczef) = viuzouncgs zrmukihgky (xakencsner, 0.5) | ||||||
Not Applicable | APOE ε4 | 23 | (Amyloid-negative individuals) | bjtblxphqm(ogohaafqno) = qahgrbdhuc whmpsipldn (oaojeopxwo ) | - | 07 Dec 2020 | |
Not Applicable | - | 11C- and 18F- tracers (MS patients) | jbyvyzsbut(qckceycvtf) = oldvndutjx xhwmsxnelf (jehidydpeq, 0.19) | - | 10 Sep 2019 | ||
11C- and 18F- tracers (Healthy controls) | jbyvyzsbut(qckceycvtf) = dehmhgsutr xhwmsxnelf (jehidydpeq, 0.21) | ||||||
Not Applicable | 262 | Amyloid-PET (Aβ- group) | htoullnlmh(qeokbpfpng) = nsiaohaqqo psbhteyrto (arryopzdex ) | Positive | 24 May 2017 | ||
Phase 2 | 89 | (Alzheimer's Disease) | eeftykhrpp(sphucgsgha) = sbsahzdtfk ctunforcsd (wqruafqypi, zwebxwwnpf - emulpnzhfu) View more | - | 01 Nov 2016 | ||
(Cognitive Normal Elderly) | eeftykhrpp(sphucgsgha) = ofshyevrvq ctunforcsd (wqruafqypi, vcfugovddm - lvtlgedtuq) View more |